Early last year, the U.S. Department of Health and Human Services (HHS) announced another milestone in the government’s effort to make prescription drugs more affordable for seniors and people with disabilities. Building on last year’s drug pricing reforms, 15 additional high-cost medications covered under Medicare Part D are now slated for official price negotiations starting in 2025, with the negotiated prices set to take effect in 2027.
Here’s what this means for medical practices, billing teams, and the patients you serve.
Why This Matters Now
What This Means for Your Practice’s Billing
As Medicare continues negotiating prices for additional medications each year, staying ahead of these changes can help practice managers:
Practices that are informed and prepared will be in the best position to help patients access essential medications more affordably while ensuring smooth, compliant billing operations. Sound like something you need to prepare for? We’ve got you covered. Reach out to speak with Travis & Tonya today!
- Educate patients early about benefit shifts
- Optimize formularies and prior authorization workflows
- Anticipate impacts on revenue cycle and reimbursement patterns
Practices that are informed and prepared will be in the best position to help patients access essential medications more affordably while ensuring smooth, compliant billing operations. Sound like something you need to prepare for? We’ve got you covered. Reach out to speak with Travis & Tonya today!
Bottom Line
Medicare’s ability to negotiate drug prices is a relatively new power established by the Inflation Reduction Act. Before this change, Medicare couldn’t directly negotiate prices with drug manufacturers, leaving seniors and taxpayers to shoulder some of the highest medication costs in the world.
The first cycle of negotiations resulted in lower maximum fair prices for 10 widely used medications, which will begin delivering savings in 2026. The newly announced second cycle adds 15 more drugs to that list (many of which treat diabetes, cancer, respiratory conditions, and chronic illnesses).
The first cycle of negotiations resulted in lower maximum fair prices for 10 widely used medications, which will begin delivering savings in 2026. The newly announced second cycle adds 15 more drugs to that list (many of which treat diabetes, cancer, respiratory conditions, and chronic illnesses).
For providers and billers focused on cash flow, patient satisfaction, and compliance, here are three key benefits:
1. Reduced patient out-of-pocket costs
Negotiated prices typically result in lower copayments and overall drug spend for Medicare Part D enrollees. This can reduce claim denials tied to cost-related nonadherence or unexpected billing disputes.
2. Smoother claims processing
With more predictable drug pricing frameworks beginning in 2027, your billing team can anticipate less variability in allowable amounts for certain high-cost prescriptions. That translates to fewer manual adjustments and easier reconciliation.
3. Improved patient adherence
High medication costs are a well-documented barrier to adherence among seniors. Lower negotiated prices could mean patients are more likely to fill and stay on their prescribed regimens, which leads to better clinical outcomes and fewer downstream billing complications from unmanaged conditions.
Note: Providers should stay updated on which specific medications have negotiated prices and the timing of implementation (starting January 1, 2027), as this will inform benefit design implications.
1. Reduced patient out-of-pocket costs
Negotiated prices typically result in lower copayments and overall drug spend for Medicare Part D enrollees. This can reduce claim denials tied to cost-related nonadherence or unexpected billing disputes.
2. Smoother claims processing
With more predictable drug pricing frameworks beginning in 2027, your billing team can anticipate less variability in allowable amounts for certain high-cost prescriptions. That translates to fewer manual adjustments and easier reconciliation.
3. Improved patient adherence
High medication costs are a well-documented barrier to adherence among seniors. Lower negotiated prices could mean patients are more likely to fill and stay on their prescribed regimens, which leads to better clinical outcomes and fewer downstream billing complications from unmanaged conditions.
Note: Providers should stay updated on which specific medications have negotiated prices and the timing of implementation (starting January 1, 2027), as this will inform benefit design implications.